Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
5.04
-0.17 (-3.26%)
At close: Sep 23, 2026, 4:00 PM EDT
5.11
+0.07 (1.39%)
After-hours: Sep 23, 2026, 5:50 PM EDT
Vanda Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Vanda Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $12.19. The average 1-year stock price forecast is 141.87% higher than the current stock price, while the lowest is $5.75 (+14.09%) and the highest is $20 (+296.83%).
Price Target: $12.19 (+141.87%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vanda Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +98.41% | Sep 23, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Initiates $17 → $12 | Buy | Initiates | $17 → $12 | +138.10% | Aug 10, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $21 → $20 | Buy | Reiterates | $21 → $20 | +296.83% | Aug 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $11 | Buy | Reiterates | $11 | +118.25% | Aug 7, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $18 | Buy | Maintains | $18 | +257.14% | May 7, 2026 |
Financial Forecast
Revenue This Year
248.66M
from 216.11M
Increased by 15.07%
Revenue Next Year
336.93M
from 248.66M
Increased by 35.50%
EPS This Year
0.96
EPS Next Year
1.04
from 0.96
Increased by 8.33%
EPS and Forward PE are based on non-GAAP adjusted numbers.